Table 1 Description of interventions assessed
From: Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis
Intervention | Description | Health facility stay | Laboratory/imaging |
|---|---|---|---|
Acute myocardial infarction | Â | 9 hospital bed days at tertiary level | CBC, blood glucose, PT, INR, aPTT and serum lipid profile (3 times) plus ECG and RFT twice |
 Aspirin | Aspirin 325 mg po daily 30 days | ||
 ACE-inhibitor | Enalapril 20 mg po daily for 30 days | ||
 Beta-blocker | Atenolol 50 mg po daily for 28 days | ||
 Aspirin + clopidogrel | Aspirin 325 mg + clopidogrel 300 mg 30 days | ||
 Thrombolytic | Streptokinase 1.5 million i-u | ||
 Primary PCI | Insertion of ballon-tipped catheter with stent into blocked area | 6 hospital bed days at tertiary level | |
Post-acute myocardial infarction | |||
 Aspirin | ASA 100 mg po daily | 4 hospital visit per year (year 1–3) 3 hospital visit per year (year 4–10) at primary hospital | CBC, LFT, RFT, serum lipid profile, serum electrolyte |
 ACE-inhibitor | Enalapril 20 mg po daily | ||
 Beta-blocker | Atenolol 50 mg po daily | ||
 Statin | Simvastatin 40 mg po daily | ||
Acute stroke | |||
 Aspirin | Aspirin 160 mg po daily for 1 month | 30 hospital bed days at level 3 | CBC,PT, INR, aPTT, serum glucose, serum lipid profile, RFT,LFT and serum electrolyte plus brain CT,ECG &CXR once |
Post-acute stroke | |||
 Aspirin | Aspirin 100 mg po daily | 4 hospital visit per year (year 1–3) 3 hospital visit per year (year 4–10) at primary hospital | CBC, RFT, LFT, serum lipid profile, serum electrolyte |
 ACE-inhibitor | Enalapril 20 mg po daily | ||
 Statin | Simvastatin 40 mg po daily | ||
Primary prevention of IHD and stroke | |||
 Anti-hypertensive treatment for SBP (>140 or >160 mmHg) | HCT 25 mg + Atenolol 50 mg po daily | 4 visit to a health center for the first year followed by 3 visits per year for the remaining 9 years. Additionally, 20 % will have 1.5 visit per year at primary hospital | RFT, serum lipid, blood glucose, U/A |
 Cholesterol lowering treatment for total cholesterol (>5.7 or >6.2 mmol/l) | Simvastatin 40 mg po daily | LFT, serum lipid, blood glucose, U/A | |
 Combination drug treatment for absolute CVD risk (>5, >15, >25, >35 %) | ASA 100 mg + Hydrochlorothiazide 25 mg + Atenolol 50 mg + Simvastatin 20 mg | RFT, LFT, serum lipid, blood glucose | |